# A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas

> **NCT03991559** · PHASE1 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Solid Tumor
- Lymphoma

## Interventions

- **DRUG:** Manganese Chloride
- **DRUG:** Anti-PD-1 antibody
- **COMBINATION_PRODUCT:** Systemic therapy

## Key facts

- **NCT ID:** NCT03991559
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-11-01
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-05-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2019-08-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03991559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03991559, "A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03991559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*